Company profile: Venatorx Pharmaceuticals
1.1 - Company Overview
Company description
- Provider of anti-infective therapies for multi-drug-resistant bacterial and viral infections, including cefepime-taniborbactam for complicated urinary tract infections and potentially hospital-acquired and ventilator-associated bacterial pneumonia; ceftibuten-ledaborbactam etzadroxil for drug-resistant Enterobacterales; and a PBP inhibitor program developing non-beta-lactam molecules.
Products and services
- Cefepime-Taniborbactam: Combination-therapy antibiotic that treats complicated urinary tract infections and potentially hospital-acquired, ventilator-associated bacterial pneumonia, combining cefepime with taniborbactam
- Penicillin Binding Protein (PBP) Inhibitor Program: Non-beta-lactam molecules in development combat multi-drug-resistant bacterial infections by targeting penicillin binding proteins
- Ceftibuten-Ledaborbactam Etzadroxil: Oral antibiotic combination that treats infections caused by drug-resistant Enterobacterales, uniting ceftibuten with ledaborbactam etzadroxil
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Venatorx Pharmaceuticals
Pardes Bio
HQ: United States
Website
- Description: Provider of direct-acting antivirals for the treatment of coronavirus, applying modern reversible-covalent chemistry to discover and develop novel oral drug candidates starting with COVID-19, as a clinical-stage biopharmaceutical company focused on improving patient access to these medicines.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Pardes Bio company profile →
NRx Pharmaceuticals
HQ: United States
Website
- Description: Provider of clinical-stage therapeutics targeting central nervous system disorders and pulmonary diseases, with investigational products including NRX-101 for suicidal bipolar depression (Phase 3), chronic pain (Phase 2), and PTSD (Phase 2), and NRX-100 (IV ketamine) for severe bipolar depression post stabilization from a suicidal crisis (Phase 3).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NRx Pharmaceuticals company profile →
Gritstone Bio
HQ: United States
Website
- Description: Provider of immunotherapies for cancer and infectious diseases, including GRANITE, a personalized neoantigen vaccine for solid tumors; SLATE, an off-the-shelf shared-neoantigen immunotherapy for KRAS-driven tumors; CORAL, prophylactic vaccines using self-amplifying mRNA; an HIV vaccine collaboration with Gilead; and EDGE, an AI platform to identify T cell targets.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Gritstone Bio company profile →
ITS Innovation
HQ: United Kingdom
Website
- Description: Provider of synthetic vaccines for mutating viruses using a T-cell vaccine platform that targets conserved viral antigens to direct immune responses, and of pemvidutide, a GLP-1/glucagon dual receptor agonist for obesity and MASH, designed to reduce body weight, liver fat, serum lipids, and address liver fat and fibrosis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ITS Innovation company profile →
Symbiomix
HQ: United States
Website
- Description: Provider of an anti-infective drug, a single-dose treatment, and innovative medicines for serious women's health infections that have long been neglected; a late-stage, privately held biopharmaceutical company.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Symbiomix company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Venatorx Pharmaceuticals
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Venatorx Pharmaceuticals
2.2 - Growth funds investing in similar companies to Venatorx Pharmaceuticals
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Venatorx Pharmaceuticals
4.2 - Public trading comparable groups for Venatorx Pharmaceuticals
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →